<DOC>
	<DOCNO>NCT00457574</DOCNO>
	<brief_summary>GMX1777 water-soluble , intravenously-administered prodrug GMX1778 . GMX1777 rapidly convert GMX1778 vivo . GMX1778 potent anti-tumor activity variety cell line model different tumor origin .</brief_summary>
	<brief_title>Safety Efficacy GMX1777 Treatment Refractory Solid Tumors Lymphomas</brief_title>
	<detailed_description>This single-center , open-label , Phase I study single-agent GMX1777 administer every 3 week patient CLL , MM , refractory solid tumor lymphomas . No investigational commercial agent therapy describe may administer intent treat patient 's malignancy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<criteria>Patients must histologically cytologically confirm solid tumor lymphoma No limitation allowable type amount prior therapy . Patients must life expectancy great 8 week Patients must normal organ marrow function Patients must willing submit blood sampling plan PK analysis Patients must ability understand willingness sign write informed consent form No agent therapy administer intent treat malignancy Patients prior exposure GMX1777 GMX1778 Uncontrolled , intercurrent illness Pregnant woman woman breast feed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>